We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+11.73%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$239M
AUM Growth
+$36.3M
(+18%)
Cap. Flow
+$21.4M
Cap. Flow
% of AUM
8.95%
Top 10 Holdings %
Top 10 Hldgs %
46.71%
Holding
69
New
7
Increased
14
Reduced
22
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMED
Amedisys
AMED
|
+$5.85M |
| 2 |
ELGX
Endologix Inc
ELGX
|
+$5.59M |
| 3 |
LDRH
LDR HOLDINGS CORP COM STK
LDRH
|
+$4.62M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$4.05M |
| 5 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$3.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omnicell
OMCL
|
+$5.36M |
| 2 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
+$4.26M |
| 3 |
Bio-Techne
TECH
|
+$2.71M |
| 4 |
ARRY
Array Biopharma Inc
ARRY
|
+$2.09M |
| 5 |
ESPR
Esperion Therapeutics
ESPR
|
+$1.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.26% |
| 2 | Energy | 3.08% |
| 3 | Real Estate | 2.24% |
| 4 | Financials | 0.24% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
51
DELISTED
Celgene Corp
CELG
| $513K | 0.21% |
4,280
| – | – |
|
|
ENDP
52
DELISTED
Endo International plc
ENDP
| $500K | 0.21% |
8,161
| – | – |
|
53
Option Care Health
OPCH
$3.45B
| $493K | 0.21% |
+70,387
| New | +$562K |
|
54
Steris
STE
$22.3B
| $477K | 0.2% |
6,330
| – | – |
|
55
Eli Lilly
LLY
$1.02T
| $463K | 0.19% |
5,495
| – | – |
|
56
Johnson & Johnson
JNJ
$618B
| $392K | 0.16% |
3,820
| – | – |
|
57
AstraZeneca
AZN
$263B
| $386K | 0.16% |
5,680
| – | – |
|
58
Amgen
AMGN
$208B
| $378K | 0.16% |
2,330
| – | – |
|
|
STJ
59
DELISTED
St Jude Medical
STJ
| $374K | 0.16% |
6,055
| – | – |
|
60
Merck
MRK
$322B
| $349K | 0.15% |
6,927
| – | – |
|
61
Pfizer
PFE
$143B
| $340K | 0.14% |
11,088
| – | – |
|
62
Myriad Genetics
MYGN
$270M
| $338K | 0.14% |
7,820
| – | – |
|
63
Sanofi
SNY
$103B
| $242K | 0.1% |
5,680
| – | – |
|
64
Bio-Rad Laboratories Class A
BIO
$8.71B
| $232K | 0.1% |
1,675
| – | – |
|
65
Agilent Technologies
A
$39.1B
| $214K | 0.09% |
+5,120
| New | +$198K |
|
66
Community Health Systems
CYH
$393M
| – | – |
-7,435
| Closed | -$263K |
|
|
ESPR
67
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-47,965
| Closed | -$1.13M |
|
|
68
Omnicell
OMCL
$1.61B
| – | – |
-172,429
| Closed | -$5.36M |
|
|
STKL
69
DELISTED
SunOpta
STKL
| – | – |
-50,230
| Closed | -$244K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q4 2015 Portfolio in Review
As of Q4 2015, First Light Asset Management held 69 positions worth $239M, up 18% from $202M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
First Light Asset Management deployed $21.4M of net new capital in Q4 2015, opening 7 new positions and adding to 14 existing holdings. Its largest new stake was Amedisys: 146,287 shares worth $5.75M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Energy and Real Estate.
On the sell side, the largest reduction was Surgalign Holdings, Inc. Common Stock, an estimated $4.26M trimmed.
- First Light Asset Management's largest Q4 2015 buy was Amedisys: 146,287 shares worth $5.75M.
- First Light Asset Management added most to Endologix Inc in Q4 2015, an estimated $5.59M increase.
- First Light Asset Management's biggest Q4 2015 reduction was Surgalign Holdings, Inc. Common Stock, cutting an estimated $4.26M.
- First Light Asset Management fully exited Omnicell in Q4 2015, selling an estimated $5.36M.
- First Light Asset Management's ten largest holdings make up 47% of its $239M portfolio in Q4 2015.
- First Light Asset Management opened 7 new positions and closed 4 in Q4 2015.
- First Light Asset Management's portfolio value rose 18% quarter-over-quarter to $239M.
Based on First Light Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.